These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 21996417

  • 1. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Nienaber CA, Ray S, Egstrup K, Pedersen TR, Køber L, Willenheimer R, Wachtell K.
    Int J Cardiol; 2013 Jun 05; 166(1):72-6. PubMed ID: 21996417
    [Abstract] [Full Text] [Related]

  • 2. Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study.
    Bang CN, Dalsgaard M, Greve AM, Køber L, Gohlke-Baerwolf C, Ray S, Rossebø AB, Egstrup K, Wachtell K.
    Int J Cardiol; 2013 Oct 03; 168(3):2322-7. PubMed ID: 23416018
    [Abstract] [Full Text] [Related]

  • 3. Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
    Bang CN, Greve AM, Boman K, Egstrup K, Gohlke-Baerwolf C, Køber L, Nienaber CA, Ray S, Rossebø AB, Wachtell K.
    Am Heart J; 2012 Apr 03; 163(4):690-6. PubMed ID: 22520536
    [Abstract] [Full Text] [Related]

  • 4. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM, Boman K, Gohlke-Baerwolf C, Kesäniemi YA, Nienaber C, Ray S, Egstrup K, Rossebø AB, Devereux RB, Køber L, Willenheimer R, Wachtell K.
    Circulation; 2012 Jan 17; 125(2):346-53. PubMed ID: 22147903
    [Abstract] [Full Text] [Related]

  • 5. Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study.
    Greve AM, Bang CN, Berg RM, Egstrup K, Rossebø AB, Boman K, Nienaber CA, Ray S, Gohlke-Baerwolf C, Nielsen OW, Okin PM, Devereux RB, Køber L, Wachtell K.
    Int J Cardiol; 2015 Feb 01; 180():122-8. PubMed ID: 25438232
    [Abstract] [Full Text] [Related]

  • 6. Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study.
    Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Devereux RB, Køber L, Ray S, Willenheimer R, Wachtell K.
    J Am Coll Cardiol; 2012 Mar 27; 59(13):1142-9. PubMed ID: 22440214
    [Abstract] [Full Text] [Related]

  • 7. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators.
    N Engl J Med; 2008 Sep 25; 359(13):1343-56. PubMed ID: 18765433
    [Abstract] [Full Text] [Related]

  • 8. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
    Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S.
    Heart Lung Circ; 2009 Oct 25; 18(5):343-6. PubMed ID: 19586799
    [Abstract] [Full Text] [Related]

  • 9. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
    Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R.
    Am J Cardiol; 2010 Dec 01; 106(11):1634-9. PubMed ID: 21094366
    [Abstract] [Full Text] [Related]

  • 10. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.
    Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray S, Wachtell K, Gerdts E.
    JACC Cardiovasc Imaging; 2009 Apr 01; 2(4):390-9. PubMed ID: 19580719
    [Abstract] [Full Text] [Related]

  • 11. Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
    Greve AM, Dalsgaard M, Bang CN, Egstrup K, Rossebø AB, Boman K, Cramariuc D, Nienaber CA, Ray S, Gohlke-Baerwolf C, Okin PM, Devereux RB, Køber L, Wachtell K.
    Am J Cardiol; 2014 Sep 01; 114(5):751-6. PubMed ID: 25048345
    [Abstract] [Full Text] [Related]

  • 12. Relation of Left Ventricular Mass to Prognosis in Initially Asymptomatic Mild to Moderate Aortic Valve Stenosis.
    Gerdts E, Rossebø AB, Pedersen TR, Cioffi G, Lønnebakken MT, Cramariuc D, Rogge BP, Devereux RB.
    Circ Cardiovasc Imaging; 2015 Nov 01; 8(11):e003644; discussion e003644. PubMed ID: 26489804
    [Abstract] [Full Text] [Related]

  • 13. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
    Rieck ÅE, Cramariuc D, Boman K, Gohlke-Bärwolf C, Staal EM, Lønnebakken MT, Rossebø AB, Gerdts E.
    Hypertension; 2012 Jul 01; 60(1):90-7. PubMed ID: 22647889
    [Abstract] [Full Text] [Related]

  • 14. Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
    Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebø A, Pedersen TR, Skjærpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Bärwolf C.
    Circulation; 2011 Mar 01; 123(8):887-95. PubMed ID: 21321152
    [Abstract] [Full Text] [Related]

  • 15. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy).
    Lund BP, Gohlke-Bärwolf C, Cramariuc D, Rossebø AB, Rieck AE, Gerdts E.
    Am J Cardiol; 2010 May 15; 105(10):1456-60. PubMed ID: 20451694
    [Abstract] [Full Text] [Related]

  • 16. Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).
    Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K.
    Circulation; 2016 Aug 09; 134(6):455-68. PubMed ID: 27486164
    [Abstract] [Full Text] [Related]

  • 17. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
    Green A, Ramey DR, Emneus M, Iachina M, Stavem K, Bolin K, McNally R, Busch-Sørensen M, Willenheimer R, Egstrup K, Kesäniemi YA, Ray S, Basta N, Kent C, Pedersen TR.
    Am J Cardiol; 2014 Nov 15; 114(10):1518-22. PubMed ID: 25267716
    [Abstract] [Full Text] [Related]

  • 18. Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM, Dalsgaard M, Bang CN, Egstrup K, Ray S, Boman K, Rossebø AB, Gohlke-Baerwolf C, Devereux RB, Køber L, Wachtell K.
    Stroke; 2014 Jul 15; 45(7):1939-46. PubMed ID: 24903982
    [Abstract] [Full Text] [Related]

  • 19. Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial).
    Rieck AE, Gerdts E, Lønnebakken MT, Bahlmann E, Cioffi G, Gohlke-Bärwolf C, Ray S, Cramariuc D.
    Cardiovasc Ultrasound; 2012 Nov 05; 10():43. PubMed ID: 23126645
    [Abstract] [Full Text] [Related]

  • 20. Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis.
    Lønnebakken MT, De Simone G, Saeed S, Boman K, Rossebø AB, Bahlmann E, Gohlke-Bärwolf C, Gerdts E.
    Heart; 2017 Sep 05; 103(18):1443-1448. PubMed ID: 28455295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.